Synthesis and Anticancer Activity of Isoquinoline‐Imidazo[1,2‐a]Pyridine Linked Sulfonyl Derivatives
ChemistrySelect · 2025-04 · 10 (15)
DOI: 10.1002/slct.202500020 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 16.04.2025. Verfasst von Mahendar Reddy Gunuguntla und 2 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Several novel imidazo[1,2‐ a ]pyridine‐isoquinoline‐linked sulfonyl derivatives were designed and synthesized in this study. These derivatives were subsequently assessed in vitro for their inhibitory effects on EGFR kinases and their antiproliferative activity against two breast cancer cell lines. Several of the compounds demonstrated satisfactory efficacy in comparison to the primary agent, erlotinib. The most promising compounds, 6‐methoxy‐2‐methyl‐1‐(2‐phenyl‐6‐(1‐((3‐(trifluoromethyl)phenyl)sulfonyl)‐1,2,3,6‐tetrahydro pyridin‐4‐yl)imidazo[1,2‐a]pyridin‐3‐yl)‐1,2,3,4‐tetrahydro isoquinoline, 6‐methoxy‐2‐methyl‐1‐(2‐phenyl‐6‐(1‐((4‐(trifluoromethoxy) phenyl) sulfonyl)‐1,2,3,6‐tetrahydropyridin‐4‐yl)imidazo[1,2‐a]pyridin‐3‐yl)‐1,2,3,4‐tetrahydroisoquinoline, and 6‐methoxy‐2‐methyl‐1‐(2‐phenyl‐6‐(1‐((3‐(trifluoromethoxy)phenyl)sulfonyl)‐1,2,3,6‐tetrahydropyridin‐4‐yl) imidazo[1,2‐a]pyridin‐3‐yl)‐1,2,3,4‐tetrahydroisoquinoline, exhibited exceptional anticancer efficacy against MCF‐7 and MDA‐MB‐231 cancer cell lines, with IC 50 values ranging from 2.69 ± 0.24 to 7.64 ± 0.15 µM. Subsequently in vitro EGFR results demonstrated that the above potent compounds were more efficacious than the conventional medicine erlotinib. The molecular interactions of more potent compounds with the human epidermal growth factor receptor (EGFR) (PDB: 4HJO), which included a co‐crystallized ligand (erlotinib) were evaluated through in silico docking studies. It was noted that the binding energies of all evaluated compounds were higher than those of the standard drug, erlotinib.
Zitieren
APA
Gunuguntla, M. R., Hanumantharayappa, M., & Koppula, S. K. (2025). Synthesis and Anticancer Activity of Isoquinoline‐Imidazo[1,2‐a]Pyridine Linked Sulfonyl Derivatives. ChemistrySelect, 10(15). https://doi.org/10.1002/slct.202500020
Vancouver
Gunuguntla MR, Hanumantharayappa M, Koppula SK. Synthesis and Anticancer Activity of Isoquinoline‐Imidazo[1,2‐a]Pyridine Linked Sulfonyl Derivatives. ChemistrySelect. 2025;10(15). doi:10.1002/slct.202500020
BibTeX
@article{Gunuguntla2025,
author = {Gunuguntla, Mahendar Reddy and Hanumantharayappa, Manjunatha and Koppula, Shiva Kumar},
title = {Synthesis and Anticancer Activity of Isoquinoline‐Imidazo[1,2‐a]Pyridine Linked Sulfonyl Derivatives},
journal = {ChemistrySelect},
year = {2025},
volume = {10},
number = {15},
doi = {10.1002/slct.202500020}
}
EUVIMED